A Double-Blind, Placebo-Controlled Trial to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis
Latest Information Update: 30 Nov 2023
Price :
$35 *
At a glance
- Drugs SPH 3127 (Primary)
- Indications Ulcerative colitis
- Focus Proof of concept; Therapeutic Use
- Sponsors Shanghai Pharmaceuticals Holding
- 24 Nov 2023 Planned End Date changed from 1 Apr 2024 to 1 Dec 2025.
- 24 Nov 2023 Planned primary completion date changed from 1 Apr 2023 to 1 Dec 2025.
- 24 Sep 2021 Status changed from not yet recruiting to recruiting.